LQDA
Liquidia Corporation
October 13, 2026 · after-hours
- Rarity
- 5.12
- Peak move
- +58.02%
- Float cap
- $1.9B
Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases such as pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It commercializes YUTREPIA, an inhaled dry powder treprostinil, in the United States and shares profit from Sandoz's generic treprostinil injection. It also develops L606 and calls on U.S. healthcare providers involved in treatment, distribution, and reimbursement.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
16 events · 9 from SEC or newswire · 2 timed with the move- Key eventTimed with the move
litigation_outcomeLiquidia entered a global settlement agreement with United Therapeutics resolving all pending litigation between the companies for a net $380.7M, paying $175M within 30 business days plus two $72.7M installments due Jan 31 and Apr 30, 2027, agreeing not to appeal the '327 patent ruling, and removing the PH-ILD indication from YUTREPIA's label, keeping YUTREPIA (treprostinil) inhalation powder available to PAH patients without disruption.
- Key eventTimed with the move
operating_metricsLiquidia reported preliminary unaudited Q3 2026 YUTREPIA net product sales of $222.7M and cash and cash equivalents of $396.1M as of September 30, 2026, ahead of its November earnings call.
insider_saleLiquidia Chief Accounting Officer Dana Boyle sold 5,892 shares at $28.48 for $167,804 on October 9, 2026, alongside option exercises of 6,356 shares.
SEC4 0001104659-26-115641insider_saleLiquidia Chief Business Officer Jason Adair sold 7,301 shares at $28.48 for $207,932 on October 9, 2026, alongside option exercises of 20,496 shares.
SEC4 0001104659-26-115640insider_saleLiquidia CEO Roger Jeffs sold 32,744 shares at $28.48 for $932,549 on October 9, 2026, alongside option exercises of 56,332 shares.
SEC4 0001104659-26-115642insider_saleLiquidia Chief Development Officer Sanjeev Khindri sold 1,101 shares at $28.48 for $31,356 on October 12, 2026.
SEC4 0001104659-26-115646insider_saleLiquidia CFO and COO Michael Kaseta sold 18,938 shares at $28.48 for $539,354 on October 9, 2026, alongside option exercises of 25,754 shares.
SEC4 0001104659-26-115644insider_saleLiquidia Chief Human Resource Officer Sarah Krepp sold 5,245 shares at $28.48 for $149,378 on October 9, 2026, alongside option exercises of 6,356 shares.
SEC4 0001104659-26-115647insider_saleLiquidia Chief Commercial Officer Scott Moomaw sold 8,863 shares at $28.48 for $252,418 on October 9, 2026, alongside option exercises of 14,932 shares.
SEC4 0001104659-26-115648insider_saleLiquidia Chief Medical Officer Rajeev Saggar sold 9,218 shares at $28.48 for $262,529 on October 9, 2026, alongside option exercises of 16,026 shares.
SEC4 0001104659-26-115649insider_saleLiquidia General Counsel Russell Schundler sold 13,692 shares at $28.48 for $389,948 on October 9, 2026, alongside option exercises of 20,334 shares.
SEC4 0001104659-26-115650spinoff_divestitureIn connection with the settlement, Liquidia terminated its promotional agreement for Treprostinil Injection and will pay an aggregate $60.3M this month to parties in the related antitrust litigation.
- Key event
class_action_filedLevi & Korsinsky announced a securities investigation of Liquidia after a court found Yutrepia infringed two valid United Therapeutics patent claims and shareholders lost roughly 57%.
analyst_ratingBofA Securities lowered its Liquidia price target to $38 from $40 while maintaining a Neutral rating, as part of its Q3 EPS preview.
analyst_ratingRaymond James reiterated its Outperform rating and $53 price target on Liquidia amid ongoing sealed filings in the '327 patent case.
insider_saleLiquidia director Stephen M. Bloch sold 235,477 common shares on October 5, 2026 at a weighted average price of $27.1262, for approximately $6.39 million in proceeds.